Purpose: Clinical pathways (CP) have increasingly been introduced into surgery for standardized elective procedures. The aim of CPs is to enhance effectiveness and quality of care by guideline specific and standardized treatment and to subsequently reduce health care costs. Due to higher disease complexity and less standardized treatment approaches, cardiology and other specialties of internal medicine have so far only seen sporadic introduction of CPs. Methods: In order to study feasibility of CP implementation into the clinical routine of a German university cardiology department, a novel checklist based CP system was broadly introduced. Key elements were 14 disease-specific CPs each detailing relevant diagnostic and therapeutic procedures and mandatory safety checks. Overall goal was to enhance standardization and cross-functional workflow transparency and thereby quality of patient care. Aim of this study was to prove CP-implementation feasibility and to evaluate clinical burden measured in average length of hospital stay (ALOS). Results were measured after 12 months of CP use (> 4500 patients included) and compared to pre CP introduction. Results: Evaluation of used CP documents showed high compliance levels for CP use among staff (CPs used in > 95% of patients) while surveys for all involved functions underlined usability. Following CP introduction no significant change in ALOS was found in "high-volume diseases" (n=380 to 780 per year) e.g., angina pectoris (LOS +2,0%; p=0,78), myocardial infarction (-3,0%; p=0,63) or heart failure (-0,1%; p=0,17), while there was significant LOS-reduction for Afib (-4,9%; p = 0,01). Hypertensive urgency patients showed an increase in LOS (+16,9%; p<0,001) while "low-volume diseases" (n=29 to 150) revealed substantial LOS reductions (syncope: -23,1%, p<0,001; DVT: -20,8%, p=0,33; PE: -10,2%, p=0,07). Conclusions: We showed feasibility of successful CP introduction within internal medicine by developing a novel checklist based approach built on cross-functional treatment guidance, transparency and regular risk checking. Significant ALOSreduction for less frequent diseases were shown, further standardization of highvolume diseases seems less promising. LOS increase after CP introduction in hypertensive urgency can most likely be attributed to increased diagnostic screening for secondary hypertension. Since long hospital stays are an increasingly relevant burden for patients, care providers and payers, a broad implementation of the introduced CP approach could be an important lever in lasting quality of care improvements within cardiology.
Purpose: To examine whether pre-diabetes is a risk factor for cerebro and cardiovascular structural and functional abnormalities (abn.), i.e. abn. small artery stiffness (C2) and abn. Carotid Intima Media Thickness (CIMT). Methods: We screened 2236 asymptomatic subjects, age 23-80, for CVD risk using Early CVD Risk Score (ECVDRS). ECVDRS consists of 10 tests: C1 and C2, BP at rest and post mild exercise (PME), CIMT, abdominal aorta and left ventricle ultrasound, retinal photography, microalbuminuria, ECG, and pro-BNP. Euglycemia (EG), pre-diabetes (PD), and diabetes (DM) were defined according to the ADA criteria. Comorbidities (CM) were defined as elevated cholestrol, BP, waist circumference. Results: Among the subjects screened, 73% (1642 of 2236) had EG, 27% (444 of 1642) of which had no CM; 22% (485 of 2236) had PD, 13% (63 of 485) of which had no CM; and 3% (74 of 2236) were diabetic, 3% (2 of 74) of which had no CM. 93% (450 of 485) of subjects with PD and 28% of the subjects with DM (21 of Table 1 74) were not taking antidiabetic medications. The presence of CVD abnormalities among the groups with EG and PD without CM is shown on table 1. Conclusions: 1. PD is a disease associated with substantially greater structural and functional abnormalities than EG, particularly abn.C2. The relationship between increased glucose levels and abn. C2 holds even when controlling for CM. 2. The difference in the prevalence of abn. C2 between EG and PD subjects is statistically significant (p = 0.0350). 3. PD is prevalent in the asymptomatic subjects (22%) screened. 4. The presence of abn. CIMT in PD subjects, as compared to EG subjects, is greater in males than females (4% difference). Whether this is due to the protective, hormonal effects in female or other factors may be subject for future studies.
